{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T07:21:25Z","timestamp":1787988085216,"version":"build-2784847793"},"reference-count":100,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2027,4,2]],"date-time":"2027-04-02T00:00:00Z","timestamp":1806624000000},"content-version":"am","delay-in-days":366,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000884","name":"Cancer Research Institute","doi-asserted-by":"publisher","award":["CRI14617"],"award-info":[{"award-number":["CRI14617"]}],"id":[{"id":"10.13039\/100000884","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006151","name":"Basic Energy Sciences","doi-asserted-by":"publisher","award":["DE-AC02-76SF00515"],"award-info":[{"award-number":["DE-AC02-76SF00515"]}],"id":[{"id":"10.13039\/100006151","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006132","name":"Office of Science","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006132","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015691","name":"National Institute of Allergy and Infectious Diseases Division of Microbiology and Infectious Diseases","doi-asserted-by":"publisher","award":["R01 AI127469"],"award-info":[{"award-number":["R01 AI127469"]}],"id":[{"id":"10.13039\/100015691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015691","name":"National Institute of Allergy and Infectious Diseases Division of Microbiology and Infectious Diseases","doi-asserted-by":"publisher","award":["U19 AI159822"],"award-info":[{"award-number":["U19 AI159822"]}],"id":[{"id":"10.13039\/100015691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015691","name":"National Institute of Allergy and Infectious Diseases Division of Microbiology and Infectious Diseases","doi-asserted-by":"publisher","award":["T32 AI145821"],"award-info":[{"award-number":["T32 AI145821"]}],"id":[{"id":"10.13039\/100015691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015691","name":"National Institute of Allergy and Infectious Diseases Division of Microbiology and Infectious Diseases","doi-asserted-by":"publisher","award":["R00 AI153465"],"award-info":[{"award-number":["R00 AI153465"]}],"id":[{"id":"10.13039\/100015691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006206","name":"Biological and Environmental Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006206","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000015","name":"U.S. Department of Energy","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000015","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Structure"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.str.2026.01.005","type":"journal-article","created":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T15:37:06Z","timestamp":1770046626000},"page":"572-587.e4","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Structural repertoire of HCV broadly neutralizing antibodies targeting the E2 front layer supersite"],"prefix":"10.1016","volume":"34","author":[{"given":"Xander E.","family":"Wilcox","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajat","family":"Punia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Mimms","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Frumento","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin R.","family":"Bailey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8722-479X","authenticated-orcid":false,"given":"Andrew I.","family":"Flyak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.str.2026.01.005_bib1","unstructured":"Global hepatitis report 2024: action for access in low- and middle-income countries https:\/\/www.who.int\/publications\/i\/item\/9789240091672."},{"key":"10.1016\/j.str.2026.01.005_bib2","unstructured":"Hepatitis C https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/hepatitis-c."},{"key":"10.1016\/j.str.2026.01.005_bib3","unstructured":"Guidance for country validation of viral hepatitis elimination and path to elimination https:\/\/www.who.int\/publications\/i\/item\/9789240078635."},{"key":"10.1016\/j.str.2026.01.005_bib4","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.15585\/mmwr.mm7132e1","article-title":"Vital Signs: Hepatitis C Treatment Among Insured Adults \u2014 United States, 2019\u20132020","volume":"71","author":"Thompson","year":"2022","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"key":"10.1016\/j.str.2026.01.005_bib5","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1111\/jvh.12859","article-title":"Understanding and addressing hepatitis C reinfection in the oral direct-acting antiviral era","volume":"25","author":"Falade-Nwulia","year":"2018","journal-title":"J. Viral Hepat."},{"key":"10.1016\/j.str.2026.01.005_bib6","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.antiviral.2014.05.015","article-title":"Update on hepatitis C virus resistance to direct-acting antiviral agents","volume":"108","author":"Poveda","year":"2014","journal-title":"Antiviral Res."},{"key":"10.1016\/j.str.2026.01.005_bib7","doi-asserted-by":"crossref","first-page":"3995","DOI":"10.3390\/v7072809","article-title":"Genetic Diversity Underlying the Envelope Glycoproteins of Hepatitis C Virus: Structural and Functional Consequences and the Implications for Vaccine Design","volume":"7","author":"Tarr","year":"2015","journal-title":"Viruses"},{"key":"10.1016\/j.str.2026.01.005_bib8","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/BF00945022","article-title":"The quasispecies of hepatitis C virus and the host immune response","volume":"19","author":"Farci","year":"1997","journal-title":"Springer Semin. Immunopathol."},{"key":"10.1016\/j.str.2026.01.005_bib9","doi-asserted-by":"crossref","first-page":"12768","DOI":"10.1073\/pnas.1609780113","article-title":"Structural flexibility at a major conserved antibody target on hepatitis C virus E2 antigen","volume":"113","author":"Kong","year":"2016","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.str.2026.01.005_bib10","doi-asserted-by":"crossref","first-page":"731","DOI":"10.37349\/ei.2022.00079","article-title":"Fight fire with fire: the need for a vaccine based on intrinsic disorder and structural flexibility","volume":"2","author":"Uversky","year":"2022","journal-title":"Explor. Immunol."},{"key":"10.1016\/j.str.2026.01.005_bib11","doi-asserted-by":"crossref","first-page":"550","DOI":"10.3389\/fimmu.2014.00550","article-title":"The Humoral Immune Response to HCV: Understanding is Key to Vaccine Development","volume":"5","author":"Cashman","year":"2014","journal-title":"Front. Immunol."},{"key":"10.1016\/j.str.2026.01.005_bib12","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-019-49454-w","article-title":"Clearance of hepatitis C virus is associated with early and potent but narrowly-directed, Envelope-specific antibodies","volume":"9","author":"Walker","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.str.2026.01.005_bib13","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1111\/j.1365-2893.2005.00651.x","article-title":"Spontaneous viral clearance following acute hepatitis C infection: a systematic review of longitudinal studies","volume":"13","author":"Micallef","year":"2006","journal-title":"J. Viral Hepat."},{"key":"10.1016\/j.str.2026.01.005_bib14","article-title":"Convergent antibody responses are associated with broad neutralization of hepatitis C virus","volume":"14","author":"Skinner","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.str.2026.01.005_bib15","doi-asserted-by":"crossref","first-page":"4786","DOI":"10.1172\/JCI130720","article-title":"Plasma deconvolution identifies broadly neutralizing antibodies associated with hepatitis C virus clearance","volume":"129","author":"Kinchen","year":"2019","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.str.2026.01.005_bib16","doi-asserted-by":"crossref","first-page":"6025","DOI":"10.1073\/pnas.0607026104","article-title":"Rapid induction of virus-neutralizing antibodies and viral clearance in a single-source outbreak of hepatitis C","volume":"104","author":"Pestka","year":"2007","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.str.2026.01.005_bib17","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.immuni.2021.12.003","article-title":"Analysis of antibodies from HCV elite neutralizers identifies genetic determinants of broad neutralization","volume":"55","author":"Weber","year":"2022","journal-title":"Immunity"},{"key":"10.1016\/j.str.2026.01.005_bib18","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1053\/j.gastro.2009.09.017","article-title":"Spontaneous Control of Primary Hepatitis C Virus Infection and Immunity Against Persistent Reinfection","volume":"138","author":"Osburn","year":"2010","journal-title":"Gastroenterology"},{"key":"10.1016\/j.str.2026.01.005_bib19","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1053\/jhep.2001.24371","article-title":"Protective Immune Response to Hepatitis C Virus in Chimpanzees Rechallenged Following Clearance of Primary Infection","volume":"33","author":"Bassett","year":"2001","journal-title":"Hepatology"},{"key":"10.1016\/j.str.2026.01.005_bib20","doi-asserted-by":"crossref","first-page":"4781","DOI":"10.1128\/JVI.77.8.4781-4793.2003","article-title":"Kinetics of CD4+ and CD8+ Memory T-Cell Responses during Hepatitis C Virus Rechallenge of Previously Recovered Chimpanzees","volume":"77","author":"Nascimbeni","year":"2003","journal-title":"J. Virol."},{"key":"10.1016\/j.str.2026.01.005_bib21","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1016\/S0140-6736(02)08435-0","article-title":"Protection against persistence of hepatitis C","volume":"359","author":"Mehta","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.str.2026.01.005_bib22","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/j.chom.2018.10.012","article-title":"Broadly Neutralizing Antibody Mediated Clearance of Human Hepatitis C Virus Infection","volume":"24","author":"Kinchen","year":"2018","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.str.2026.01.005_bib23","doi-asserted-by":"crossref","DOI":"10.1172\/JCI160058","article-title":"Repeated exposure to heterologous hepatitis C viruses associates with enhanced neutralizing antibody breadth and potency","volume":"132","author":"Frumento","year":"2022","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.str.2026.01.005_bib24","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.immuni.2023.12.004","article-title":"Neutralizing antibodies evolve to exploit vulnerable sites in the HCV envelope glycoprotein E2 and mediate spontaneous clearance of infection","volume":"57","author":"Frumento","year":"2024","journal-title":"Immunity"},{"key":"10.1016\/j.str.2026.01.005_bib25","doi-asserted-by":"crossref","first-page":"2140","DOI":"10.1002\/hep.27013","article-title":"Clearance of Hepatitis C infection is associated with early appearance of broad neutralizing antibody responses","volume":"59","author":"Osburn","year":"2014","journal-title":"Hepatol. Baltim. Md"},{"key":"10.1016\/j.str.2026.01.005_bib26","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.53169","article-title":"An ultralong CDRH2 in HCV neutralizing antibody demonstrates structural plasticity of antibodies against E2 glycoprotein","volume":"9","author":"Flyak","year":"2020","journal-title":"eLife"},{"key":"10.1016\/j.str.2026.01.005_bib28","doi-asserted-by":"crossref","first-page":"535","DOI":"10.3390\/v6020535","article-title":"CD81 and Hepatitis C Virus (HCV) Infection","volume":"6","author":"F\u00e9n\u00e9ant","year":"2014","journal-title":"Viruses"},{"key":"10.1016\/j.str.2026.01.005_bib29","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1128\/JVI.78.3.1448-1455.2004","article-title":"CD81 Is Required for Hepatitis C Virus Glycoprotein-Mediated Viral Infection","volume":"78","author":"Zhang","year":"2004","journal-title":"J. Virol."},{"key":"10.1016\/j.str.2026.01.005_bib30","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2018.01315","article-title":"The Neutralizing Face of Hepatitis C Virus E2 Envelope Glycoprotein","volume":"9","author":"Tzarum","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.str.2026.01.005_bib31","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.antiviral.2014.02.013","article-title":"The past, present and future of neutralizing antibodies for hepatitis C virus","volume":"105","author":"Ball","year":"2014","journal-title":"Antiviral Res."},{"key":"10.1016\/j.str.2026.01.005_bib32","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2018.01194","article-title":"Mapping Determinants of Virus Neutralization and Viral Escape for Rational Design of a Hepatitis C Virus Vaccine","volume":"9","author":"Keck","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.str.2026.01.005_bib33","doi-asserted-by":"crossref","first-page":"6205","DOI":"10.1073\/pnas.1114927109","article-title":"Human broadly neutralizing antibodies to the envelope glycoprotein complex of hepatitis C virus","volume":"109","author":"Giang","year":"2012","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.str.2026.01.005_bib34","doi-asserted-by":"crossref","first-page":"7005","DOI":"10.1128\/JVI.00586-11","article-title":"Neutralizing Monoclonal Antibodies against Hepatitis C Virus E2 Protein Bind Discontinuous Epitopes and Inhibit Infection at a Postattachment Step","volume":"85","author":"Sabo","year":"2011","journal-title":"J. Virol."},{"key":"10.1016\/j.str.2026.01.005_bib35","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1016\/j.chom.2018.10.009","article-title":"HCV Broadly Neutralizing Antibodies Use a CDRH3 Disulfide Motif to Recognize an E2 Glycoprotein Site that Can Be Targeted for Vaccine Design","volume":"24","author":"Flyak","year":"2018","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.str.2026.01.005_bib36","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1126\/science.1243876","article-title":"Hepatitis C virus E2 envelope glycoprotein core structure","volume":"342","author":"Kong","year":"2013","journal-title":"Science"},{"key":"10.1016\/j.str.2026.01.005_bib27","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/S0966-842X(99)01590-5","article-title":"Quasispecies in viral persistence and pathogenesis of hepatitis C virus","volume":"7","author":"Forns","year":"1999","journal-title":"Trends Microbiol."},{"key":"10.1016\/j.str.2026.01.005_bib37","doi-asserted-by":"crossref","first-page":"10451","DOI":"10.1128\/JVI.05259-11","article-title":"Mapping a region of hepatitis C virus E2 that is responsible for escape from neutralizing antibodies and a core CD81-binding region that does not tolerate neutralization escape mutations","volume":"85","author":"Keck","year":"2011","journal-title":"J. Virol."},{"key":"10.1016\/j.str.2026.01.005_bib38","doi-asserted-by":"crossref","first-page":"6067","DOI":"10.1128\/JVI.00252-08","article-title":"A point mutation leading to hepatitis C virus escape from neutralization by a monoclonal antibody to a conserved conformational epitope","volume":"82","author":"Keck","year":"2008","journal-title":"J. Virol."},{"key":"10.1016\/j.str.2026.01.005_bib39","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.coviro.2021.05.002","article-title":"Structural Perspectives on HCV Humoral Immune Evasion Mechanisms","volume":"49","author":"Sevvana","year":"2021","journal-title":"Curr. Opin. Virol."},{"key":"10.1016\/j.str.2026.01.005_bib40","doi-asserted-by":"crossref","first-page":"291","DOI":"10.3390\/vaccines9030291","article-title":"Mechanisms of Hepatitis C Virus Escape from Vaccine-Relevant Neutralizing Antibodies","volume":"9","author":"Vel\u00e1zquez-Moctezuma","year":"2021","journal-title":"Vaccines"},{"key":"10.1016\/j.str.2026.01.005_bib41","doi-asserted-by":"crossref","first-page":"805","DOI":"10.3390\/v13050805","article-title":"To Include or Occlude: Rational Engineering of HCV Vaccines for Humoral Immunity","volume":"13","author":"Schlotthauer","year":"2021","journal-title":"Viruses"},{"key":"10.1016\/j.str.2026.01.005_bib42","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.aaz6225","article-title":"Proof of concept for rational design of hepatitis C virus E2 core nanoparticle vaccines","volume":"6","author":"He","year":"2020","journal-title":"Sci. Adv."},{"key":"10.1016\/j.str.2026.01.005_bib43","doi-asserted-by":"crossref","first-page":"837","DOI":"10.3390\/v13050837","article-title":"Structure-Based and Rational Design of a Hepatitis C Virus Vaccine","volume":"13","author":"Guest","year":"2021","journal-title":"Viruses"},{"key":"10.1016\/j.str.2026.01.005_bib44","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1186\/s12929-020-00669-4","article-title":"Hepatitis C virus vaccine design: focus on the humoral immune response","volume":"27","author":"Sepulveda-Crespo","year":"2020","journal-title":"J. Biomed. Sci."},{"key":"10.1016\/j.str.2026.01.005_bib45","doi-asserted-by":"crossref","first-page":"3980","DOI":"10.1038\/s41467-023-39659-z","article-title":"Structure of engineered hepatitis C virus E1E2 ectodomain in complex with neutralizing antibodies","volume":"14","author":"Metcalf","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.str.2026.01.005_bib46","doi-asserted-by":"crossref","first-page":"7271","DOI":"10.1038\/s41467-022-34961-8","article-title":"Induction of cross-neutralizing antibodies by a permuted hepatitis C virus glycoprotein nanoparticle vaccine candidate","volume":"13","author":"Sliepen","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.str.2026.01.005_bib47","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1126\/science.1222908","article-title":"Highly conserved protective epitopes on influenza B viruses","volume":"337","author":"Dreyfus","year":"2012","journal-title":"Science"},{"key":"10.1016\/j.str.2026.01.005_bib48","doi-asserted-by":"crossref","first-page":"2935","DOI":"10.1016\/j.celrep.2017.08.084","article-title":"Antibody 27F3 Broadly Targets Influenza A Group 1 and 2 Hemagglutinins through a Further Variation in VH1-69 Antibody Orientation on the HA Stem","volume":"20","author":"Lang","year":"2017","journal-title":"Cell Rep."},{"key":"10.1016\/j.str.2026.01.005_bib49","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1038\/nature11371","article-title":"Structural and genetic basis for development of broadly neutralizing influenza antibodies","volume":"489","author":"Lingwood","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.str.2026.01.005_bib50","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/j.immuni.2019.09.001","article-title":"Germline-encoded affinity for cognate antigen enables vaccine-amplification of a human broadly neutralizing response against influenza virus","volume":"51","author":"Sangesland","year":"2019","journal-title":"Immunity"},{"key":"10.1016\/j.str.2026.01.005_bib51","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abb1328","article-title":"A VH1-69 antibody lineage from an infected Chinese donor potently neutralizes HIV-1 by targeting the V3 glycan supersite","volume":"6","author":"Kumar","year":"2020","journal-title":"Sci. Adv."},{"key":"10.1016\/j.str.2026.01.005_bib52","article-title":"VH1-69 Utilizing Antibodies Are Capable of Mediating Non-neutralizing Fc-Mediated Effector Functions Against the Transmitted\/Founder gp120","volume":"9","author":"Smith","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.str.2026.01.005_bib53","doi-asserted-by":"crossref","first-page":"2749","DOI":"10.1080\/22221751.2022.2140611","article-title":"Shared IGHV1-69-encoded neutralizing antibodies contribute to the emergence of L452R substitution in SARS-CoV-2 variants","volume":"11","author":"Yan","year":"2022","journal-title":"Emerg. Microbes Infect."},{"key":"10.1016\/j.str.2026.01.005_bib54","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/j.immuni.2021.02.013","article-title":"Functional convergence of a germline-encoded neutralizing antibody response in rhesus macaques immunized with HCV envelope glycoproteins","volume":"54","author":"Chen","year":"2021","journal-title":"Immunity"},{"key":"10.1016\/j.str.2026.01.005_bib55","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1126\/science.abn9884","article-title":"Structure of the hepatitis C virus E1E2 glycoprotein complex","volume":"378","author":"Torrents de la Pe\u00f1a","year":"2022","journal-title":"Science"},{"key":"10.1016\/j.str.2026.01.005_bib56","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.aav1882","article-title":"Genetic and structural insights into broad neutralization of hepatitis C virus by human VH1-69 antibodies","volume":"5","author":"Tzarum","year":"2019","journal-title":"Sci. Adv."},{"key":"10.1016\/j.str.2026.01.005_bib57","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2022.110859","article-title":"Sites of vulnerability in HCV E1E2 identified by comprehensive functional screening","volume":"39","author":"Pfaff-Kilgore","year":"2022","journal-title":"Cell Rep."},{"key":"10.1016\/j.str.2026.01.005_bib73","doi-asserted-by":"crossref","first-page":"e02070-18","DOI":"10.1128\/JVI.02070-18","article-title":"Broadly Neutralizing Antibodies Targeting New Sites of Vulnerability in Hepatitis C Virus E1E2","volume":"93","author":"Colbert","year":"2019","journal-title":"J. Virol."},{"key":"10.1016\/j.str.2026.01.005_bib58","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/nm1698","article-title":"Broadly neutralizing antibodies protect against hepatitis C virus quasispecies challenge","volume":"14","author":"Law","year":"2008","journal-title":"Nat. Med."},{"key":"10.1016\/j.str.2026.01.005_bib59","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1006735","article-title":"Probing the antigenicity of hepatitis C virus envelope glycoprotein complex by high-throughput mutagenesis","volume":"13","author":"Gopal","year":"2017","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.str.2026.01.005_bib60","doi-asserted-by":"crossref","first-page":"9499","DOI":"10.1073\/pnas.1202924109","article-title":"Structural basis of hepatitis C virus neutralization by broadly neutralizing antibody HCV1","volume":"109","author":"Kong","year":"2012","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.str.2026.01.005_bib61","doi-asserted-by":"crossref","first-page":"E6946","DOI":"10.1073\/pnas.1614942113","article-title":"Global mapping of antibody recognition of the hepatitis C virus E2 glycoprotein: Implications for vaccine design","volume":"113","author":"Pierce","year":"2016","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.str.2026.01.005_bib62","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1003364","article-title":"Structural basis of HCV neutralization by human monoclonal antibodies resistant to viral neutralization escape","volume":"9","author":"Krey","year":"2013","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.str.2026.01.005_bib63","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1016\/j.immuni.2024.03.001","article-title":"Convergent evolution and targeting of diverse E2 epitopes by human broadly neutralizing antibodies are associated with HCV clearance","volume":"57","author":"Ogega","year":"2024","journal-title":"Immunity"},{"key":"10.1016\/j.str.2026.01.005_bib64","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1038\/s42003-025-08239-w","article-title":"Cryo-EM structures of HCV E2 glycoprotein bound to neutralizing and non-neutralizing antibodies determined using bivalent Fabs as fiducial markers","volume":"8","author":"Shahid","year":"2025","journal-title":"Commun. Biol."},{"key":"10.1016\/j.str.2026.01.005_bib65","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1053\/j.gastro.2019.11.282","article-title":"Antibody Responses to Immunization With HCV Envelope Glycoproteins as a Baseline for B-Cell\u2013Based Vaccine Development","volume":"158","author":"Chen","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1016\/j.str.2026.01.005_bib66","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abb5642","article-title":"An alternate conformation of HCV E2 neutralizing face as an additional vaccine target","volume":"6","author":"Tzarum","year":"2020","journal-title":"Sci. Adv."},{"key":"10.1016\/j.str.2026.01.005_bib67","doi-asserted-by":"crossref","DOI":"10.1103\/PhysRevLett.100.020603","article-title":"Well-Tempered Metadynamics: A Smoothly Converging and Tunable Free-Energy Method","volume":"100","author":"Barducci","year":"2008","journal-title":"Phys. Rev. Lett."},{"key":"10.1016\/j.str.2026.01.005_bib68","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1038\/s41586-021-03913-5","article-title":"Structural insights into hepatitis C virus receptor binding and entry","volume":"598","author":"Kumar","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.str.2026.01.005_bib69","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1172\/JCI78794","article-title":"Naturally selected hepatitis C virus polymorphisms confer broad neutralizing antibody resistance","volume":"125","author":"Bailey","year":"2015","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.str.2026.01.005_bib70","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.coviro.2021.07.003","article-title":"Mechanisms of HCV resistance to broadly neutralizing antibodies","volume":"50","author":"Frumento","year":"2021","journal-title":"Curr. Opin. Virol."},{"key":"10.1016\/j.str.2026.01.005_bib71","doi-asserted-by":"crossref","DOI":"10.1186\/s12859-018-2459-9","article-title":"GLUE: A flexible software system for virus sequence data","volume":"19","author":"Singer","year":"2018","journal-title":"BMC Bioinf."},{"key":"10.1016\/j.str.2026.01.005_bib72","doi-asserted-by":"crossref","first-page":"323","DOI":"10.3390\/v11040323","article-title":"Interpreting Viral Deep Sequencing Data with GLUE","volume":"11","author":"Singer","year":"2019","journal-title":"Viruses"},{"key":"10.1016\/j.str.2026.01.005_bib74","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1053\/j.gastro.2021.10.005","article-title":"An Antigenically Diverse, Representative Panel of Envelope Glycoproteins for Hepatitis C Virus Vaccine Development","volume":"162","author":"Salas","year":"2022","journal-title":"Gastroenterology"},{"key":"10.1016\/j.str.2026.01.005_bib75","doi-asserted-by":"crossref","first-page":"8449","DOI":"10.1073\/pnas.0703039104","article-title":"Hepatitis C virus epitope-specific neutralizing antibodies in Igs prepared from human plasma","volume":"104","author":"Zhang","year":"2007","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.str.2026.01.005_bib76","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.92872","article-title":"Broadly neutralizing antibodies with few somatic mutations and hepatitis C virus clearance","volume":"2","author":"Bailey","year":"2017","journal-title":"JCI Insight"},{"key":"10.1016\/j.str.2026.01.005_bib77","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1007772","article-title":"Broadly neutralizing antibodies from an individual that naturally cleared multiple hepatitis C virus infections uncover molecular determinants for E2 targeting and vaccine design","volume":"15","author":"Keck","year":"2019","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.str.2026.01.005_bib78","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/gm410","article-title":"Interleukin-28B polymorphisms and hepatitis C virus clearance","volume":"5","author":"Chayama","year":"2013","journal-title":"Genome Med."},{"key":"10.1016\/j.str.2026.01.005_bib79","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1002653","article-title":"Human monoclonal antibodies to a novel cluster of conformational epitopes on HCV E2 with resistance to neutralization escape in a genotype 2a isolate","volume":"8","author":"Keck","year":"2012","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.str.2026.01.005_bib80","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1016\/j.cell.2024.12.015","article-title":"Designed mosaic nanoparticles enhance cross-reactive immune responses in mice","volume":"188","author":"Wang","year":"2025","journal-title":"Cell"},{"key":"10.1016\/j.str.2026.01.005_bib81","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2025.2545601","article-title":"What does AlphaFold3 learn about antibody and nanobody docking, and what remains unsolved?","volume":"17","author":"Hitawala","year":"2025","journal-title":"mAbs"},{"key":"10.1016\/j.str.2026.01.005_bib82","doi-asserted-by":"crossref","DOI":"10.1002\/pro.4865","article-title":"Evaluation of AlphaFold antibody\u2013antigen modeling with implications for improving predictive accuracy","volume":"33","author":"Yin","year":"2024","journal-title":"Protein Sci."},{"key":"10.1016\/j.str.2026.01.005_bib83","doi-asserted-by":"crossref","DOI":"10.1002\/pro.5127","article-title":"A comparison of antibody\u2013antigen complex sequence-to-structure prediction methods and their systematic biases","volume":"33","author":"McCoy","year":"2024","journal-title":"Protein Sci."},{"key":"10.1016\/j.str.2026.01.005_bib84","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.71854","article-title":"An entropic safety catch controls hepatitis C virus entry and antibody resistance","volume":"11","author":"Stejskal","year":"2022","journal-title":"eLife"},{"key":"10.1016\/j.str.2026.01.005_bib85","first-page":"151","article-title":"Phenotypical stability of a human hepatoma cell line, HuH-7, in long-term culture with chemically defined medium","volume":"75","author":"Nakabayashi","year":"1984","journal-title":"GANN Jpn. J. Cancer Res."},{"key":"10.1016\/j.str.2026.01.005_bib86","doi-asserted-by":"crossref","DOI":"10.1099\/jgv.0.001512","article-title":"Optimized cell systems for the investigation of hepatitis C virus E1E2 glycoproteins","volume":"102","author":"Kalemera","year":"2021","journal-title":"J. Gen. Virol."},{"key":"10.1016\/j.str.2026.01.005_bib87","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1107\/S0907444909052925","article-title":"PHENIX: a comprehensive Python-based system for macromolecular structure solution","volume":"66","author":"Adams","year":"2010","journal-title":"Acta Crystallogr. D Biol. Crystallogr."},{"key":"10.1016\/j.str.2026.01.005_bib88","doi-asserted-by":"crossref","first-page":"2126","DOI":"10.1107\/S0907444904019158","article-title":"Coot: model-building tools for molecular graphics","volume":"60","author":"Emsley","year":"2004","journal-title":"Acta Crystallogr. D Biol. Crystallogr."},{"key":"10.1016\/j.str.2026.01.005_bib89","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1107\/S2059798317016035","article-title":"CCP4i2: the new graphical user interface to the CCP4 program suite","volume":"74","author":"Potterton","year":"2018","journal-title":"Acta Crystallogr. D Struct. Biol."},{"key":"10.1016\/j.str.2026.01.005_bib90","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1016\/j.jmb.2007.05.022","article-title":"Inference of Macromolecular Assemblies from Crystalline State","volume":"372","author":"Krissinel","year":"2007","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.str.2026.01.005_bib91","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1107\/S0907444910048675","article-title":"iMOSFLM: a new graphical interface for diffraction-image processing with MOSFLM","volume":"67","author":"Battye","year":"2011","journal-title":"Acta Crystallogr. D Biol. Crystallogr."},{"key":"10.1016\/j.str.2026.01.005_bib92","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1107\/S0907444910045749","article-title":"Overview of the CCP4 suite and current developments","volume":"67","author":"Winn","year":"2011","journal-title":"Acta Crystallogr. D Biol. Crystallogr."},{"key":"10.1016\/j.str.2026.01.005_bib93","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1107\/S0021889807021206","article-title":"Phaser crystallographic software","volume":"40","author":"McCoy","year":"2007","journal-title":"J. Appl. Crystallogr."},{"key":"10.1016\/j.str.2026.01.005_bib94","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1038\/nsmb.3115","article-title":"Privateer: software for the conformational validation of carbohydrate structures","volume":"22","author":"Agirre","year":"2015","journal-title":"Nat. Struct. Mol. Biol."},{"key":"10.1016\/j.str.2026.01.005_bib95","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1107\/S0907444909042073","article-title":"MolProbity: all-atom structure validation for macromolecular crystallography","volume":"66","author":"Chen","year":"2010","journal-title":"Acta Crystallogr. D Biol. Crystallogr."},{"key":"10.1016\/j.str.2026.01.005_bib96","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.softx.2015.06.001","article-title":"GROMACS: High performance molecular simulations through multi-level parallelism from laptops to supercomputers","volume":"1","author":"Abraham","year":"2015","journal-title":"SoftwareX"},{"key":"10.1016\/j.str.2026.01.005_bib97","doi-asserted-by":"crossref","first-page":"3257","DOI":"10.1021\/ct300400x","article-title":"Optimization of the Additive CHARMM All-Atom Protein Force Field Targeting Improved Sampling of the Backbone \u03d5, \u03c8 and Side-Chain \u03c71 and \u03c72 Dihedral Angles","volume":"8","author":"Best","year":"2012","journal-title":"J. Chem. Theory Comput."},{"key":"10.1016\/j.str.2026.01.005_bib98","doi-asserted-by":"crossref","first-page":"3314","DOI":"10.1021\/ct300418h","article-title":"MMPBSA.py: An Efficient Program for End-State Free Energy Calculations","volume":"8","author":"Miller","year":"2012","journal-title":"J. Chem. Theory Comput."},{"key":"10.1016\/j.str.2026.01.005_bib99","doi-asserted-by":"crossref","first-page":"6281","DOI":"10.1021\/acs.jctc.1c00645","article-title":"gmx_MMPBSA: A New Tool to Perform End-State Free Energy Calculations with GROMACS","volume":"17","author":"Vald\u00e9s-Tresanco","year":"2021","journal-title":"J. Chem. Theory Comput."},{"key":"10.1016\/j.str.2026.01.005_bib100","series-title":"Hepatitis C Virus Protocols","first-page":"441","article-title":"Standardized Method for the Study of Antibody Neutralization of HCV Pseudoparticles (HCVpp)","author":"Bailey","year":"2019"}],"container-title":["Structure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0969212626000079?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0969212626000079?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T14:48:44Z","timestamp":1775141324000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0969212626000079"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":100,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["S0969212626000079"],"URL":"https:\/\/doi.org\/10.1016\/j.str.2026.01.005","relation":{},"ISSN":["0969-2126"],"issn-type":[{"value":"0969-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Structural repertoire of HCV broadly neutralizing antibodies targeting the E2 front layer supersite","name":"articletitle","label":"Article Title"},{"value":"Structure","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.str.2026.01.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}